Epigenetic therapies for neuroblastoma: immunogenicity awakens
The development of immunotherapies for neuroblastoma remains challenging owing to the low immunogenicity of neuroblastoma cells, as reflected by the low expression of one of the main triggers of immune recognition, the major histocompatibility complex class I (MHC‐I). Cornel et al. showed that epige...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-05-01
|
| Series: | Molecular Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/1878-0261.13404 |
| _version_ | 1797833426446843904 |
|---|---|
| author | Carlos Jiménez Lucas Moreno Miguel F. Segura |
| author_facet | Carlos Jiménez Lucas Moreno Miguel F. Segura |
| author_sort | Carlos Jiménez |
| collection | DOAJ |
| description | The development of immunotherapies for neuroblastoma remains challenging owing to the low immunogenicity of neuroblastoma cells, as reflected by the low expression of one of the main triggers of immune recognition, the major histocompatibility complex class I (MHC‐I). Cornel et al. showed that epigenetic modulation of neuroblastoma cells with a histone deacetylase inhibitor can boost the expression of major histocompatibility complex class I, among other immune receptors, priming their recognition by T‐ and natural killer cells. By leveraging the developmentally related aberrant epigenetic landscapes of neuroblastoma, these discoveries pave the way to overcome a major limitation in the field of neuroblastoma immunotherapy. |
| first_indexed | 2024-04-09T14:22:57Z |
| format | Article |
| id | doaj.art-866e3a0fadcf45a2afe16749205dd5a5 |
| institution | Directory Open Access Journal |
| issn | 1574-7891 1878-0261 |
| language | English |
| last_indexed | 2024-04-09T14:22:57Z |
| publishDate | 2023-05-01 |
| publisher | Wiley |
| record_format | Article |
| series | Molecular Oncology |
| spelling | doaj.art-866e3a0fadcf45a2afe16749205dd5a52023-05-04T13:53:08ZengWileyMolecular Oncology1574-78911878-02612023-05-0117571872110.1002/1878-0261.13404Epigenetic therapies for neuroblastoma: immunogenicity awakensCarlos Jiménez0Lucas Moreno1Miguel F. Segura2Human Technopole Milan ItalyGroup of Childhood Cancer and Blood Disorders, Vall d'Hebron Research Institute (VHIR) Universitat Autònoma de Barcelona (UAB) SpainGroup of Childhood Cancer and Blood Disorders, Vall d'Hebron Research Institute (VHIR) Universitat Autònoma de Barcelona (UAB) SpainThe development of immunotherapies for neuroblastoma remains challenging owing to the low immunogenicity of neuroblastoma cells, as reflected by the low expression of one of the main triggers of immune recognition, the major histocompatibility complex class I (MHC‐I). Cornel et al. showed that epigenetic modulation of neuroblastoma cells with a histone deacetylase inhibitor can boost the expression of major histocompatibility complex class I, among other immune receptors, priming their recognition by T‐ and natural killer cells. By leveraging the developmentally related aberrant epigenetic landscapes of neuroblastoma, these discoveries pave the way to overcome a major limitation in the field of neuroblastoma immunotherapy.https://doi.org/10.1002/1878-0261.13404histone deacetylase inhibitorsimmunotherapymajor histocompatibility complex class Ineuroblastoma |
| spellingShingle | Carlos Jiménez Lucas Moreno Miguel F. Segura Epigenetic therapies for neuroblastoma: immunogenicity awakens Molecular Oncology histone deacetylase inhibitors immunotherapy major histocompatibility complex class I neuroblastoma |
| title | Epigenetic therapies for neuroblastoma: immunogenicity awakens |
| title_full | Epigenetic therapies for neuroblastoma: immunogenicity awakens |
| title_fullStr | Epigenetic therapies for neuroblastoma: immunogenicity awakens |
| title_full_unstemmed | Epigenetic therapies for neuroblastoma: immunogenicity awakens |
| title_short | Epigenetic therapies for neuroblastoma: immunogenicity awakens |
| title_sort | epigenetic therapies for neuroblastoma immunogenicity awakens |
| topic | histone deacetylase inhibitors immunotherapy major histocompatibility complex class I neuroblastoma |
| url | https://doi.org/10.1002/1878-0261.13404 |
| work_keys_str_mv | AT carlosjimenez epigenetictherapiesforneuroblastomaimmunogenicityawakens AT lucasmoreno epigenetictherapiesforneuroblastomaimmunogenicityawakens AT miguelfsegura epigenetictherapiesforneuroblastomaimmunogenicityawakens |